Navigation Links
Rondaxe and TD2 form strategic drug development alliance
Date:2/18/2010

SAN FRANCISCO Feb. 18, 2010 TGen Drug Development (TD2) and Rondaxe Enterprises today announced a strategic alliance that will help emerging companies speed new high-quality treatments to cancer patients.

Rondaxe, a drug development consulting company in Syracuse, N.Y., helps emerging pharmaceutical and biotechnology companies navigate through all phases of the drug development and commercialization process. The company specializes in drug chemistry, manufacturing and controls (CMC), quality assurance and control, regulatory affairs and virtual business development.

TD2, a non-profit Scottsdale subsidiary of the Phoenix-based Translational Genomic Research Institute (TGen), specializes in guiding drug companies through the complexities of setting up and conducting clinical trials, and moving promising drug candidates through the federal review process of the U.S. Food and Drug Administration.

"We are excited to work with Rondaxe, since effective CMC management is key to the successful application and approval processes of the FDA, and moving new anti-cancer treatments to market where they can provide patient benefit," said Dr. Stephen Gately, President and Chief Science Officer at TD2.

Jeffrey M. Evans, Ph.D., co-founder and managing partner of Rondaxe, said, "Our clients will benefit measurably from the 'TD2 Solution' by receiving clear clinical and regulatory development path guidance and service support."

Today's announcement was made during InformexUSA, the world's leading fine and custom chemical industry trade show, which runs through Friday, Feb. 19, at the Moscone Convention Center in downtown San Francisco.

The TD2-Rondaxe alliance is designed to bridge a critical gap between chemistry and translational medicine. This blend of expertise will speed research discoveries through the regulatory process to bring new compounds to patients in a risk-reduced and cost-effective manner. TD2 and Rondaxe teams will focus on maximizing their clients' value proposition throughout the early stages of drug-development.

Rondaxe will provide drug development and manufacturing strategies with expertise in chemical, fermentation, drug product and analytical development, supply chain strategy, manufacturing operations, quality control, and quality assurance.

TD2 offers an integrated suite of tools that includes preclinical support, clinical trials and regulatory affairs, "The TD2 Solution."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
2. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
3. IBM and ETH Zurich form strategic partnership in nanoscience
4. Cuellars Safe and Lock Announces Strategic Alliance with Absolute Access and Security
5. Strategic farming practices could help mitigate global warming
6. Compendium of pancreatic cancer biomarkers established as strategic approach to early-detection
7. BIO-key(R) Enters Strategic Partnership With Nlets
8. Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products
9. BIO-key(R) Enters Strategic Partnership With Nlets
10. BIO-key Retains Former Senior FBI Official as Strategic Advisor and Consultant
11. Gender, coupled with diabetes, affects vascular disease development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
Breaking Biology Technology: